Oral Mucositis Market Size, Share, Growth Trends and Forecast Report 2023-2030
Market Overview
Oral Mucositis (OM) is a condition characterized by ulceration and inflammation of the mucosal membranes of the mouth and throat. It is a frequent side effect and significant consequence for people getting head and neck cancer therapies that include radiation and chemotherapy.
Oral mucositis affects around 40% of chemotherapy and all radiation patients. Intractable pain and inflammation, increased infection risk, starvation, dehydration, trouble speaking, and increased narcotic usage are all serious OM consequences. These sores, if left untreated, may develop into life-threatening infections. Diagnostics, including biopsy and fungal testing, are used to identify oral mucositis. Some of the products that can be used to treat OM include antiseptic mouth rinses, pain relievers, water-soluble lubricating agents, bland rinses, and mucosal coating agents.
Download Free PDF Sample: Click Here
Market Growth Analysis
As per DataM Intelligence’s latest report, the “Global Oral Mucositis Market” is estimated to grow at a CAGR of 5.6% during the forecast period 2023 – 2030.
Market Drivers
Increasing Prevalence of Cancers to Lead Market Growth
The side effects of chemotherapy & radiation on oral mucosa lead to oral mucositis. The market for mucositis therapies is predicted to expand over the estimated period, owing to the growing incidence of cancer patients globally. As a result, the need for mucositis treatment is growing rapidly, which is likely to boost the growth and share of the oral mucositis market over the forecast period. The mucositis therapeutics industry benefits from improved clinical trials and partnership tactics.
Furthermore, increasing research to produce mucositis medications is projected to drive market growth and demand.
Significant Health Concerns to Drive Market Demand and Growth
Various escalating health issues will drive the mucositis medications market, in addition to the increasing instances of mouth and neck cancers globally. The mucositis medications market has risen drastically in developed nations as a result of increasing oral cavity infections, poor oral hygiene, and a sedentary lifestyle.
The expanding and ongoing technical improvement in diagnosis and treatment will also drive the market’s growth and demand. This will result in huge income and profit creation for investors and manufacturers worldwide, resulting in product market expansion.
Market Trends
Oral mucositis induced by chemotherapy treatment will account for a considerable part of the market since chemotherapy is mostly used to treat cancer. The medication formulations available in the mucositis market include cryotherapy, antioxidants, anti-inflammatory medicines, low-level laser treatment (LLLT), mouthwashes, and barriers. As a result, the product’s market growth will see an extraordinary surge throughout the forecast period.
Oral Mucositis Market: Segmentation Analysis
The Oral Mucositis Market is segmented by cause into chemotherapy, radiotherapy, and hematopoietic stem cell transplantation; by treatment into mouthwash, growth factors, low-level laser therapy (LLLT), cryotherapy, and others; and by end-users into hospitals, dental clinics, oncology centres, research institutes, and others.
By Cause: The Chemotherapy Segment Leads the Market With 46.5% of the Market Share.
The chemotherapy segment dominated the market, accounting for 46.5% of market revenue. The market for chemotherapy-induced oral mucositis is growing with the global prevalence of cancer patients and the number of chemotherapy treatments delivered. Owing to the radiation adverse effects and the oral mucositis-causing side effects of cytotoxic chemotherapy drugs, the market for chemotherapy-induced oral mucositis is expected to increase considerably throughout the projection period.
For more detailed information: Click Here
Industry Developments
- In December 2022, Galera Therapeutics, Inc. filed to the FDA a new drug application (NDA) seeking approval of avasopasem manganese (GC4419) for radiotherapy-induced oral mucositis in people with head and neck cancer who are undergoing standard treatment. The application is supported by data from 678 participants who took part in the GT-201 (NCT02508389) and ROMAN (NCT03689712) studies.
- In September 2022, Sanofi India and GlaxoSmithKline (GSK) Pharmaceuticals incurred considerable income losses when several of their medications were reduced in price in order to be listed on India’s essential medicines list. GSK’s oral antibiotic drug, which accounts for a significant portion of the company’s income, has been added to the List of Essential Medicines. The pharmaceuticals on the list will have their costs capped in order to make them more inexpensive and accessible to the general population.
Regional Insights
By region, the global oral mucositis market is segmented into North America, Europe, South America, Asia Pacific, and Middle East and Africa.
North America Region Holds the Largest Market Share
The North American region dominates the oral mucositis market due to the rising innovations, investments, mergers, acquisitions, collaborations, and partnerships in the region. The easing of the pandemic, increased disposable income, lower inflation, and the return of routine healthcare services are the primary drivers driving the market’s growth and industry share. As a result, the market for mucositis treatments and therapies will see an unparalleled surge.
Competitive Landscape
The major global players operating in the oral mucositis market include EUSA Pharma Inc., Daewoong Pharmaceutical Co., Soligenix, Inc., Sunstar Suisse SA, Swedish Orphan Biovitrum Ltd., Amgen Inc., Bausch Health, EKR Therapeutics, Inc., Access Pharmaceuticals, Inc., Eisai Inc., Innovation Pharmaceuticals, Moberg Pharma AB, among others.
EUSA Pharma Inc. Overview
EUSA Pharma Inc is a global specialty pharmaceutical company. The company creates, manufactures, and sells specialized pharmaceutical products. The company provides oncology drugs, oncology support, and critical care. EUSA Pharma sells its products all over the world. EUSA Pharma Clinical Research and Development is involved in improving the use of its products to maximize the clinical benefit for patients who have cancer or rare diseases. The company is a subsidiary of Jazz Pharmaceuticals.
About DataM Intelligence
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.
Trending Reports
Media Contact
Company Name: DataM Intelligence
Contact Person: Sai.K
Email: [email protected]
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/
Media Contact
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Send Email
Phone: 08774414866
Address:DATAM INTELLIGENCE 4MARKET RESEARCH LLP Ground floor, DSL Abacus IT Park, Industrial Development Area, Uppal, Hyderabad, Telangana 500039
City: HYDERABAD
State: Telangana
Country: India
Website: https://www.datamintelligence.com/research-report/oral-mucositis-market
